LG Technology Ventures and existing investors Novo, SR One and Takeda Ventures all took part in a round that will support the advance of Arcellx's immuno-oncology cell therapies.
US-based cancer therapy developer Arcellx has secured $85m in a series B round that included diversified conglomerate LG and pharmaceutical firms Novo, Takeda and GlaxoSmithKline (GSK).
The round was co-led by venture capital firms Aju IB Investment and Quan Capital and included Mirae Asset Venture Investment, Mirae Asset Capital, JVC Investment Partners, New Enterprise Associates (NEA) and certain funds managed by Clough Capital Partners.
LG, GSK and Takeda participated through subsidiaries LG Technology Ventures, SR One and Takeda Ventures. Arcellx…
